Loading
Life sciences · Journal article
Current Issues in Molecular Biology · August 7, 2026
Encouraging direction, but not yet definitive.
HTL-001, a HOX/PBX interaction inhibitor, reduced viability in multiple TNBC cell lines with higher sensitivity than normal breast cells, and reduced tumour growth in a mouse xenograft model. Synergistic effects were observed with epigenetic modifiers and paclitaxel in vitro. This represents early mechanistic evidence for HOX/PBX as a TNBC target, but clinical translation remains unproven.
Preclinical in vitro and in vivo study. Multiple TNBC-derived cell lines (specific lines and count unstated); immortalised normal breast cell line as control; MDA-MB-231 xenograft model in mice. Intervention: HTL-001, a HOX/PBX interaction inhibitor; optionally combined with epigenetic modifiers or paclitaxel. Compared with: Immortalised normal breast cells; vehicle or single-agent comparators in combination studies (specific controls not detailed).
All tested TNBC-derived cell lines exhibited high HOX dysregulation compared to immortalised normal breast cells and greater sensitivity to HTL-001-induced apoptosis HTL-001 shows synergistic interactions with epigenetic modifiers (5-azacytidine, Trichostatin A) and paclitaxel in vitro HTL-001 significantly reduced tumour growth in a mouse tumour flank model of MDA-MB-231 TNBC cells
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest HOX/PBX inhibition as a novel therapeutic avenue for TNBC, but the work remains preclinical. Clinicians should await Phase 1 human safety and efficacy data before considering clinical application.
A sound preclinical study demonstrating HTL-001 efficacy in TNBC cell lines and a mouse xenograft model, but lacking human clinical data and powered efficacy trials needed to establish clinical utility.
As stated by the source record.
These findings suggest HOX/PBX inhibition as a novel therapeutic avenue for TNBC, but the work remains preclinical. Clinicians should await Phase 1 human safety and efficacy data before considering clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Triple negative breast cancer (TNBC) continues to have a poor prognosis relative to other forms of this disease. Previous studies have shown that the HOX family of transcription factors generally show increased expression in breast cancer and may have a primarily pro-oncogenic role. In this study, we assessed the sensitivity of a range of TNBC-derived cell lines to an inhibitor of HOX protein function, HTL-001, which blocks the interaction between HOX proteins and the Pre-B-cell Leukaemia Homeobox (PBX) cofactor. The sensitivity of cell lines was measured by MTS viability assays, and gene expression by RT-qPCR. Combination studies were performed with epigenetic modifiers (5-azacytidine (5-aza), Trichostatin A (TSA)) and standard-of-care chemotherapeutic drugs including Paclitaxel. A mouse tumour flank model of MDA-MB-231 cells was used to assess response to HTL-001, paclitaxel, or combination therapy. All the cell lines exhibited high levels of HOX dysregulation compared to an immortalised line derived from normal breast cells, and greater sensitivity to HTL-001-induced apoptosis. Epigenetic changes have previously been shown to be key modulators of HOX expression and, correspondingly, we show that reversing epigenetic changes in these cell lines significantly alters HOX expression and generally reduces sensitivity to HTL-001. In addition, HTL-001 shows synergistic interactions with several established chemotherapeutic agents in vitro. We further demonstrate that HTL-001 can significantly reduce tumour growth in a mouse model of TNBC. Our findings indicate that HOX/PBX dimers are a potential therapeutic target in this cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.